Navigation Links
Enhancement of chemotherapy by prevention of tumor cell repair
Date:2/20/2014

This news release is available in French.

Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team of researchers directed by Frdric Coin, Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg (a Joint Inserm/CNRS/University of Strasbourg Research Unit), has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy.

Their results are published in Chemistry & Biology.

UV rays, physical or chemical agentsthe human body is constantly subject to environmental insults that cause more or less damage to our DNA. The body has therefore developed a whole system for proofreading and repair. Among these mechanisms, NER (Nucleotide Excision Repair) has been studied for several years by the researchers in a team led by Frdric Coin and Jean-Marc Egly at IGBMC. This mechanism can thus detect a lesion, and then replace the damaged DNA fragment with an intact fragment.

Cytotoxic chemotherapy is aimed at blocking the division of malignant cells in order to prevent tumour growth. Included among the drugs used to treat many cancers such as colorectal, face and neck, testicular, bladder, ovarian and lung cancers are medications based on platinum. These drugs bind to cellular DNA, induce damage in the latter, and thus prevent its replication. Blocking DNA repair mechanisms, specifically NER activity, would help to potentiate chemotherapy by reducing the resistance of cells to the treatment.

The researchers at IGBMC therefore sought a drug that would inhibit NER activity. They thus tested over 1,200 therapeutic drugs and demonstrated the action of spironolactone, a drug already used for the treatment of hypertension, on NER activity. Specifically, the researchers showed that its action, when combined with that of platinum derivatives, caused a substantial increase in cytotoxicity for malignant colonic and ovarian cells.

Since spironolactone is already in use for other purposes, it does not require a new application for marketing authorisation, and its side-effects are already known. This result thus bodes very well for the rapid development of new chemotherapy protocols that include spironolactone.

Immunofluorescence labelling, 1 h after treatment, of XPC proteins (in red) and XPB proteins (in green) involved in NER activity. On the right, treatment with spironolactone induces rapid degradation of XPB, which explains its inhibition of NER.


'/>"/>

Contact: Frédéric Coin
mfrederic.coin@igbmc.fr
33-388-653-200
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related biology news :

1. MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution
2. Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award
3. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
4. Neuroblastoma: Autophagy protects from chemotherapy
5. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
6. Discovery may help prevent chemotherapy-induced anemia
7. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
8. New way to kill lymphoma without chemotherapy
9. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
10. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
11. New biomarker for common lung cancer predicts responses to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... ... 03, 2016 , ... Flagship Biosciences, the leader in ... Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, ... Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 ...
(Date:5/3/2016)... 2016  Dr. Thomas P. McHugh , an ... The Woodlands, Texas , now offers SculpSure, the ... fat cells in just 25-minutes, leaving a slimmer figure ... of Americans report feeling bothered by excess weight and ... are a growing industry. This innovative new approach to ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... its clients in mind, the fresh look and added functionality give the agricultural ... years have seen a dynamic shift in agriculture – from precision farming via ...
(Date:4/29/2016)... ... 2016 , ... Proove Biosciences, Inc ., the commercial ... of the Proove Health Foundation . The Foundation is a non-profit organization ... of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As part of ...
Breaking Biology Technology: